Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600 mutant melanoma an open label non randomized study

Home / Abstract / Factors associated with disease progression in patients treated with trametinib in combination with dabrafenib for unresectable advanced BRAFV600 mutant melanoma an open label non randomized study